1. Introduction {#sec1}
===============

Esophageal carcinoma (EC) is the sixth leading cause of cancer mortality in males and the ninth leading cause of cancer mortality in females in 2012 worldwide \[[@B1]\]. The highest incident rates of EC are found in Eastern Asia, Southern Africa, and Eastern Africa and the lowest incidence rate of EC is found in Western Africa \[[@B1]\]. Esophageal carcinoma is usually 3 to 4 times more common among men than women. The 5-year overall survival ranges from 15% to 25% \[[@B2]\]. In China, it is predicted that EC is the fourth leading cause of cancer deaths in males and females after lung and bronchus, stomach, and liver in 2015 \[[@B3]\].

EC is classified as esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) according to histological type and ESCC is the predominant histological type of EC in the world \[[@B2]\]. It is reported that tobacco consumption, alcohol consumption, and low intake of fruits and vegetables are major risk factors for ESCC \[[@B4]\]. Overweight, obesity, gastroesophagus reflux disease (GERD), and Barrett\'s esophagus increase incidence risk of EAC \[[@B1], [@B5]\].

In addition to the above-mentioned environmental factors, abnormal expression of miRNA and genes and methylation of genes and SNPs are associated with EC tumorigenesis and development. miR-219-1 rs107822G \> A polymorphism might significantly decrease ESCC risk through changing individual susceptibility to Chinese Kazakhs \[[@B5]\]. The cases carrying the GG variant homozygote have a significant 2.81-fold increased risk of EC \[[@B6]\]. miR-330-3p promotes cell growth, cell migration, and invasion and inhibits cisplatin-induced apoptosis in ESCC cells via suppression of PDCD4 expression \[[@B7]\]. miR-199a-5p downregulation contributes to enhancing EC cell proliferation through upregulation of mitogen-activated protein kinase kinase kinase-11 \[[@B8]\]. DACT2 is frequently methylated in human esophageal cancer; methylated DATC2 accelerates esophageal cancer development by activating Wnt signaling \[[@B9]\]. RUNX3 methylation is associated with an increased risk, progression, and poor survival in EC \[[@B10]\].

Currently, the molecular mechanism of EC was unclear. In this study, we used bioinformatics methods to analyze the mRNA expression data of EC, which were available on the GEO database, to identify key genes and pathways in EC, aiming to provide valuable information for further pathogenesis mechanism elucidation and provide ground work for therapeutic targets identification for EC.

2. Materials and Methods {#sec2}
========================

2.1. Expression Profile Microarray {#sec2.1}
----------------------------------

Gene expression profiles data were downloaded from the Gene Expression Omnibus (GEO) data repository (<http://www.ncbi.nlm.nih.gov/geo/>). The datasets of patients receiving preoperative treatment before oesophagectomy and cell lines receiving drug stimulus were excluded. Total of 5 mRNA expression datasets of EC tissues/cell lines comprising GSE53625, GSE33810, GSE17351, GSE9982, and GSE12737 were included in our study.

2.2. Identification of DEGs {#sec2.2}
---------------------------

The raw data of the mRNA expression profiles were downloaded and analyzed by R language software \[[@B11]\]. Background correction, quartile data normalization, and probe summarization were applied for the original data. The limma \[[@B12]\] method in Bioconductor (<http://www.bioconductor.org/>) was used to identify genes which were differentially expressed between EC and normal controls; the significance of DEGs was calculated by*t*-test and was represented by *p* value. To reduce the risk of false positives, *p* values were adjusted for multiple testing using the Benjamini-Hochberg False Discovery Rate (FDR) method. The corrected *p* value was represented by FDR \[[@B13]\]. FDR \< 0.05 were considered as the cutoff values for DEG screening.

2.3. Gene Ontology Analysis {#sec2.3}
---------------------------

GO is a useful tool for collecting a large number of gene annotation terms \[[@B14]\]. The Database for Annotation, Visualization, and Integrated Discovery (DAVID) \[[@B15]\], is bioinformatics resources consisting of an integrated biological knowledgebase and analytic tools aimed at systematically extracting biological functional annotation from large gene/protein lists, such as being derived from high-throughput genomic experiments. To gain the in-depth understanding of the biological functions of DEGs, DAVID tool was used to obtain the enriched GO terms of DEGs based on the hypergeometric distribution to compute *p* values, which were corrected by the Benjamini and Hochberg FDR method for multiple hypothesis testing. FDR \< 0.05 was set as the threshold value.

2.4. KEGG Enrichment Pathways {#sec2.4}
-----------------------------

KEGG is a database resource for understanding functions of genes list from molecular level \[[@B16]\]. GeneCoDis3 is a valuable tool to functionally interpret results from experimental techniques in genomics \[[@B17]\]. This web-based application integrates different sources of information for finding groups of genes with similar biological meaning. The enrichment analysis of GeneCoDis3 is essential in the interpretation of high-throughput experiments. In the study, GeneCoDis3 software was used to test the statistical enrichment of DEGs in KEGG pathways. *p* \< 0.05 was set as the threshold value.

2.5. PPI Interaction Network {#sec2.5}
----------------------------

The Biological General Repository for Interaction Datasets (BioGRID: <http://thebiogrid.org/>) is an open access archive of genetic and protein interactions that are curated from the primary biomedical literature for all major model organism species including budding yeast*Saccharomyces cerevisiae*, the fission yeast*Schizosaccharomyces pombe*, and the model plant*Arabidopsis thaliana*. In a word, BioGRID is a depository for genetic and protein interactions based on experimental verification \[[@B18]\]. The top 10 upregulated genes and top 10 downregulated genes between EC and normal controls were subjected to BioGRID database to get the predicted PPIs of these DEGs. The PPIs were visualized in Cytoscape \[[@B17]\].

2.6. qRT-PCR Validation {#sec2.6}
-----------------------

Total RNA of fresh paired EC tumor and adjacent nontumor specimens were extracted using TRIzol reagent (Invitrogen, CA, USA). The SuperScript III Reverse Transcription Kit (Invitrogen, CA, USA) was used to synthesize the cDNA. qRT-PCR reactions were performed using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) on the Applied Biosystems 7500 (Foster City, CA, USA). *β*-actin was used as internal control for mRNA detected. The relative expression of genes was calculated using the comparative Ct methods \[[@B19]\]. The PCR primers were used as shown in supplementary Table S3 in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/2968106>.

3. Results {#sec3}
==========

3.1. Identification of DEGs {#sec3.1}
---------------------------

Five mRNA expression profiles including 208 EC samples and 195 normal controls were downloaded and analyzed, as shown in [Table 1](#tab1){ref-type="table"}. 208 EC samples comprised 207 squamous cell carcinoma samples and 1 adenocarcinoma sample. 1955 DEGs were identified in EC compared to normal control, including 919 upregulated and 1036 downregulated genes. The top 10 significantly upregulated and downregulated genes were listed in [Table 2](#tab2){ref-type="table"}. The most significantly up- and downregulated genes were CDK4 and THSD4, respectively. The full list of DEGs in EC was shown in supplementary Table S1.

3.2. GO Analysis of DEGs {#sec3.2}
------------------------

Following GO analyses for up- and downregulated DEGs, significant GO terms including biological process, cellular component, and molecular function were collected. For upregulated DEGs, cell cycle was the most significant enrichment of biological process; membrane-enclosed lumen was the highest enrichment of cellular component; nucleotide binding was the highest enrichment of molecular function, as shown in [Table 3](#tab3){ref-type="table"}. For downregulated DEGs, response to wounding was the most significant enrichment of biological process; actin cytoskeleton was the highest enrichment of cellular component and cytoskeletal protein binding was the highest enrichment of molecular function, as shown in [Table 4](#tab4){ref-type="table"}.

3.3. KEGG Enrichment Pathways of DEGs {#sec3.3}
-------------------------------------

Following KEGG enrichment analysis for DEGs, significant KEGG terms were collected. The pathways enriched by 919 upregulated DEGs were mainly related to cell cycle, RNA transport, and p53 signaling pathway ([Table 5](#tab5){ref-type="table"}). 1036 downregulated DEGs were significantly enriched in Endocytosis, focal adhesion, and vascular smooth muscle contraction, as shown in [Table 6](#tab6){ref-type="table"}.

3.4. PPI Network Construction {#sec3.4}
-----------------------------

Based on data from the BioGRID database, the PPI network was the top 10 upregulated and downregulated DEGs which were constructed by Cytoscape software ([Figure 1](#fig1){ref-type="fig"}). The network consisted of 451 nodes and 499 edges. In the PPI networks the nodes with high degree are defined as hub proteins. The most significant hub proteins in the PPI network were CDK4 (degree = 132) and CCT3 (degree = 127); as shown in [Figure 1](#fig1){ref-type="fig"}, the red circular nodes represent upregulated DEGs and green circular nodes represent downregulated DEGs, respectively.

3.5. qRT-PCR Validation of DEGs in EC Tissues {#sec3.5}
---------------------------------------------

To validate the microarray analysis data, the expression of DEGs including CCT3, CDK4, MYBL2, CENPF, CDKN3, CDCA3, THSD4, and SIM2 was detected by qRT-PCR in 5 paired EC tumor and adjacent nontumor tissues. The 5 patients received surgery treatment in Fourth Hospital of Hebei Medical University. The histological type of 5 subjects was ESCC and the detailed information of subjects was shown in supplementary Table S2. As shown in Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"} the expression level of CCT3 and MYBL2 was significantly upregulated in ESCC. CDK4, CENPF, CDKN3, and CDCA3 had the upregulation tendency in ESCC (Figures [2(c)](#fig2){ref-type="fig"}--[2(f)](#fig2){ref-type="fig"}), respectively. SIM2 was significantly downregulated in ESCC ([Figure 2(g)](#fig2){ref-type="fig"}). THSD4 had the downregulation tendency in ESCC ([Figure 2(h)](#fig2){ref-type="fig"}). The qRT-PCR results were matched with the microarray analysis.

4. Discussion {#sec4}
=============

CDK4 was identified as the most significantly upregulated gene in our microarray analysis and it had an upregulated tendency in EC tissues through the qRT-PCR validation. CDK4 was the hub protein and interacted with 132 genes in the regulatory network. CDK4 was significantly enriched in cell cycle, measles, small cell lung cancer, and pathways in cancer. CDK4 encodes cyclin-dependent kinase 4, a member of the Ser/Thr protein kinase family, which plays an important role in cell cycle G1 phase progression and G1/S transition. In our study, CDK1, CDK6, and CDK10 showed upregulation in EC. CDK1, CDK6, and CDK4 were significantly enriched in cell cycle pathway. CDK4 is overexpression in several cancer comprising of breast cancer, pancreas cancer, clear cell renal cell carcinoma, and colorectal cancer \[[@B20]--[@B23]\]. Downregulation of MALAT1 (long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1) inhibits breast cancer cell proliferation and cell cycle progression*in vitro* and*in vivo* through miR-124 downregulation and CDK4 upregulation \[[@B20], [@B24]\]. Overexpression of cyclin D1/CDK4 is regulated by CEACAM6 and promotes cell proliferation in human pancreatic carcinoma \[[@B21]\]. CDK4 and CDK6 expression are decreased by miR-1 and contribute to inhibition of cell cycle progression and metastasis in clear cell renal cell carcinoma \[[@B22]\].

CCT3 was the top 3 upregulation DEGs in EC ([Table 2](#tab2){ref-type="table"}). The qRT-PCR displayed that CCT3 was significantly upregulated in EC, which was in accordance with our microarray analysis ([Figure 2](#fig2){ref-type="fig"}). CCT3 interacted with 127 genes in the PPI network ([Figure 1](#fig1){ref-type="fig"}). CCT3 encodes chaperonin containing TCP1 subunit 3, a molecular chaperone, which is a member of the chaperonin containing TCP1 complex (CCT). In our study, CCT2, CCT4, CCT5, and CCT7 were upregulated in EC compared to normal controls, respectively. CCT3 depletion suppresses cell proliferation by inducing mitotic arrest at prometaphase and apoptosis eventually in HCC*in vitro*. Clinically, overexpression of CCT3 predicts poor prognosis in hepatocellular carcinoma patients after hepatectomy \[[@B25], [@B26]\]. CCT3 is significantly associated with carboplatin resistance in ovarian cancer patients after surgery treatment \[[@B27]\]. The proteomic-based study shows that patients with cholangiocarcinoma (CCA) which are positive for CCT3 and CCT3 might be potential biomarker for the diagnosis of CCA \[[@B28]\]. To our knowledge, this is the first report about CCT3 expressed status in EC and the biological function of upregulated CCT3 in EC needs further exploration.

THSD4 was the most downregulated DGE in EC through microarray analysis. The expression level of THSD4 had no significance in EC compared to normal controls but had the downregulated tendency in EC. THSD4 encodes thrombospondin type 1 domain containing 4. The methylated status of THSD4 shows positive correlation with short survival in glioblastoma patients and hypermethylation of THSD4 indicates poor survival \[[@B29]\]. The expression of THSD4 is regulated by GATA3 and mediates transformation of normal cells into breast cancer through deregulation of THSD4 \[[@B30]\]. The role of downregulated THSD4 in EC is unclear, and the investigation needs to be carried out in the future.

SIM2 was significantly downregulated in EC ([Figure 2](#fig2){ref-type="fig"}). SIM2 encodes single-minded family bHLH transcription factor 2. SIM2-s was dysregulated in glioma, prostate cancer, breast cancer, colorectal cancer, and ESCC \[[@B31]--[@B35]\]. SIM2s is downregulated in human breast cancer samples and it suppresses tumor activity through decreased expression of matrix metalloprotease-3. In breast cancer, SIM2s is downregulated. It is a key regulator of mammary-ductal development. SIM2s inhibition is associated with cell invasive and EMT-like phenotype through regulating matrix metalloprotease-3 expression \[[@B34], [@B36]\] It is reported that SIM2s is downregulated in 70% ESCC tissues, which is consistent with our qRT-PCR verification \[[@B35]\]. SIM2 overexpression results in increase of drug- and radio-sensitivities in ESCC*in vivo* and*in vitro* and patients with high expression level of SIM2 are associated with favorable prognosis before chemotherapy \[[@B35]\]. It is suggested that SIM2 plays vital roles in EC onset and progression.

MYBL2, CENPF, CDKN3, and CDCA3 were upregulated in EC tissues ([Figure 2](#fig2){ref-type="fig"}).*MYBL2* is frequently amplified in gastroesophageal cancer cell lines and Barrett\'s adenocarcinoma \[[@B37], [@B38]\].*CENPF* is frequently amplified in region around 1q32-q41 and is overexpressed in ESCC cell line \[[@B39]\]. CDKN3 is upregulated in 68.0% of the epithelial ovarian cancer samples and lung adenocarcinoma patients and is correlated with poor patient survival \[[@B40], [@B41]\]. CDCA3 expression status in EC was firstly reported in our study. The molecular mechanism of MYBL2, CENPF, CDKN3, and CDCA3 in EC is needed to be explored.

5. Conclusions {#sec5}
==============

We identified 1955 DEGs comprising 919 upregulated genes and 1036 downregulated genes in EC. DEGs including CDK4, CCT3, THSD4, and SIM2 were verified in EC tissues through qRT-PCR. CDK4 and CCT3 were hub proteins in the PPI interaction network. We found that some genes including CDK4, CCT3, THSD4, and SIM2 may play essential roles in EC through cell cycle, RNA transport, Endocytosis, and focal adhesion signaling pathways. The genes could also be considered as potential candidate biomarkers for therapeutic targets for this malignancy. Furthermore, our study would shed light on the molecular mechanism underlying tumorigenesis of EC.

Supplementary Material {#supplementary-material-sec}
======================

###### 

The expression level of 8 candidate genes with dysregulation in esophageal carcinoma were validated through qRT-PCR. The primers for amplification of 8 genes in qRT-PCR was shown in supplementary S3.
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![The protein-protein network of top 10 up- and downregulated DEGs in EC. The green circular nodes represent downregulation DEGs in EC; the red circular nodes represent downregulation DEGs in EC. Solid lines indicate interaction between DEGs and proteins.](GRP2016-2968106.001){#fig1}

![The qRT-PCR validation of the expression level of DEGs in EC compared to adjacent nontumor tissues. (a) CCT3; (b) MYBL2; (c) CDK4; (d) CENPF; (e) CDKN3; (f) CDCA3; (g) SIM2; (h) THSD4. EC: esophageal carcinoma; CON: adjacent nontumor tissues of ESCC. At least three independent experiments were performed for statistical evaluation. qRT-PCR experimental data were expressed as means ± SD. The statistical significance was evaluated using Student\'s*t*-test and *p* \< 0.05 was considered as a significant difference.](GRP2016-2968106.002){#fig2}

###### 

The information of gene expression microarrays of EC.

  GEO ID     Platform                                                                Case : control   Sample type                          Country   Time   Author
  ---------- ----------------------------------------------------------------------- ---------------- ------------------------------------ --------- ------ -----------------------------
  GSE53625   GPL18109 CBC *Homo sapiens* lncRNA + mRNA microarray V2.0               179 : 179        Esophageal squamous cell carcinoma   China     2014   Li et al. \[[@B42]\]
  GSE33810   GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array   2 : 1            Esophageal squamous cell carcinoma   HK        2013   Chen et al. \[[@B43]\]
  GSE17351   GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array   5 : 5            Esophageal squamous cell carcinoma   USA       2009   Long et al. \[[@B46]\]
  GSE9982    GPL1928 CodeLink Human 20K ver4.1                                       20 : 2           Esophageal squamous cancer           Japan     2006   Shimokuni et al. \[[@B44]\]
  GSE12737   GPL7262 Human ORESTES NoMatch 4.8k v1.0                                 2 : 8            Squamous cell & adenocarcinoma       Brazil    2009   Mello et al. \[[@B45]\]

EC: esophageal carcinoma.

###### 

The top 10 up-regulated and top 10 down-regulated DEGs in EC.

  Gene ID                    Gene symbol   Official full name                                                             FDR
  -------------------------- ------------- ------------------------------------------------------------------------------ -----------
  *Upregulated (top 10)*                                                                                                   
  1019                       CDK4          Cyclin-dependent kinase 4                                                      0.0002252
  4605                       MYBL2         MYB protooncogene like 2                                                       0.0002252
  7203                       CCT3          Chaperonin containing TCP1 subunit 3                                           0.0003378
  83461                      CDCA3         Cell division cycle associated 3                                               0.0004504
  1033                       CDKN3         Cyclin-dependent kinase inhibitor 3                                            0.0004504
  1063                       CENPF         Centromere protein F                                                           0.0004729
  9156                       EXO1          Exonuclease 1                                                                  0.0004729
  79075                      DSCC1         DNA replication and sister chromatid cohesion 1                                0.0005405
  4751                       NEK2          NIMA related kinase 2                                                          0.0005405
  *Downregulated (top 10)*                                                                                                 
  79875                      THSD4         Thrombospondin type 1 domain containing 4                                      0.0002252
  79026                      AHNAK         AHNAK nucleoprotein                                                            0.0004729
  6493                       SIM2          Single-minded family bHLH transcription factor 2                               0.0004729
  7881                       KCNAB1        Potassium voltage-gated channel subfamily A member regulatory beta subunit 1   0.0005405
  90865                      IL33          Interleukin 33                                                                 0.0008812
  55287                      TMEM40        Transmembrane protein 40                                                       0.0008812
  966                        CD59          CD59 molecule                                                                  0.0015608
  5121                       PCP4          Purkinje cell protein 4                                                        0.0015608
  22885                      ABLIM3        Actin binding LIM protein family member 3                                      0.0016629
  3590                       IL11RA        Interleukin 11 receptor subunit alpha                                          0.0016629

EC: esophageal carcinoma; FDR: false discovery rate.

###### 

GO annotation of upregulated DEGs in EC.

  GO ID                  GO term                                        Count   *p*-value      FDR
  ---------------------- ---------------------------------------------- ------- -------------- --------------
  *Biological process*                                                                          
  GO:0007049             Cell cycle                                     152     4.10*E* − 13   7.59*E* − 10
  GO:0022402             Cell cycle process                             118     3.44*E* − 12   6.36*E* − 09
  GO:0022403             Cell cycle phase                               90      2.00*E* − 10   3.71*E* − 07
  GO:0000278             Mitotic cell cycle                             82      5.34*E* − 10   9.87*E* − 07
  GO:0051301             Cell division                                  67      8.80*E* − 09   1.63*E* − 05
  GO:0000279             M phase                                        70      6.27*E* − 08   1.16*E* − 04
  GO:0000087             M phase of mitotic cell cycle                  49      3.38*E* − 06   0.0062547
  GO:0000280             Nuclear division                               48      4.65*E* − 06   0.0086014
  GO:0007067             Mitosis                                        48      4.65*E* − 06   0.0086014
  GO:0048285             Organelle fission                              49      6.41*E* − 06   0.011854
  GO:0033554             Cellular response to stress                    95      2.02*E* − 05   0.0373322
  *Cellular component*                                                                          
  GO:0031974             Membrane-enclosed lumen                        276     1.12*E* − 10   1.65*E* − 07
  GO:0043233             Organelle lumen                                270     2.41*E* − 10   3.56*E* − 07
  GO:0043232             Intracellular non-membrane-bounded organelle   359     8.74*E* − 10   1.29*E* − 06
  GO:0043228             Non-membrane-bounded organelle                 359     8.74*E* − 10   1.29*E* − 06
  GO:0070013             Intracellular organelle lumen                  259     4.54*E* − 09   6.71*E* − 06
  GO:0031981             Nuclear lumen                                  216     1.90*E* − 08   2.80*E* − 05
  GO:0000775             Chromosome, centromeric region                 36      2.52*E* − 08   3.72*E* − 05
  GO:0005829             Cytosol                                        192     1.36*E* − 06   0.0020016
  GO:0015630             Microtubule cytoskeleton                       92      4.62*E* − 06   0.0068255
  GO:0000793             Condensed chromosome                           32      6.75*E* − 06   0.009972
  GO:0000779             Condensed chromosome, centromeric region       21      7.55*E* − 06   0.011151
  GO:0044427             Chromosomal part                               69      9.92*E* − 06   0.0146408
  GO:0005635             Nuclear envelope                               43      1.37*E* − 05   0.0202598
  GO:0000777             Condensed chromosome kinetochore               19      1.48*E* − 05   0.0219025
  GO:0005694             Chromosome                                     78      1.75*E* − 05   0.02589
  GO:0000776             Kinetochore                                    22      2.72*E* − 05   0.0401619
  *Molecular function*                                                                          
  GO:0000166             Nucleotide binding                             305     5.53*E* − 06   0.0090275
  GO:0017076             Purine nucleotide binding                      266     5.55*E* − 06   0.0090714
  GO:0030554             Adenyl nucleotide binding                      223     1.07*E* − 05   0.0175078
  GO:0001883             Purine nucleoside binding                      225     1.49*E* − 05   0.0242774
  GO:0032555             Purine ribonucleotide binding                  252     2.35*E* − 05   0.0383944
  GO:0032553             Ribonucleotide binding                         252     2.35*E* − 05   0.0383944
  GO:0001882             Nucleoside binding                             225     2.44*E* − 05   0.0398342

EC: esophageal carcinoma; FDR: false discovery rate.

###### 

GO annotation of downregulated DEGs in EC.

  GO ID                  GO term                                                                    Count   *p* value      FDR
  ---------------------- -------------------------------------------------------------------------- ------- -------------- --------------
  *Biological process*                                                                                                      
  GO:0009611             Response to wounding                                                       65      1.98*E* − 08   3.57*E* − 05
  GO:0042060             Wound healing                                                              33      5.75*E* − 08   1.04*E* − 04
  GO:0030097             Hemopoiesis                                                                32      1.85*E* − 05   0.0334238
  GO:0007167             Enzyme linked receptor protein signaling pathway                           41      2.03*E* − 05   0.0365533
  GO:0030036             Actin cytoskeleton organization                                            31      2.05*E* − 05   0.0370181
  GO:0048534             Hemopoietic or lymphoid organ development                                  34      2.06*E* − 05   0.0372021
  GO:0007155             Cell adhesion                                                              69      2.10*E* − 05   0.0378896
  GO:0042692             Muscle cell differentiation                                                21      2.14*E* − 05   0.0386651
  GO:0022610             Biological adhesion                                                        69      2.19*E* − 05   0.0394751
  GO:0007178             Transmembrane receptor protein serine/threonine kinase signaling pathway   19      2.53*E* − 05   0.0456886
  *Cellular component*                                                                                                      
  GO:0015629             Actin cytoskeleton                                                         36      5.84*E* − 06   0.008305
  GO:0005794             Golgi apparatus                                                            83      7.36*E* − 06   0.0104637
  GO:0005856             Cytoskeleton                                                               118     1.23*E* − 05   0.0175254
  *Molecular function*                                                                                                      
  GO:0008092             Cytoskeletal protein binding                                               59      8.55*E* − 07   0.0013403

EC: esophageal carcinoma; FDR: false discovery rate.

###### 

The KEGG pathway enrichment of up-regulated DEGs in EC.

  KEGG ID    KEGG terms                                Count   FDR            Genes
  ---------- ----------------------------------------- ------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa04110   Cell cycle                                19      7.86*E* − 08   CDK6, CCNE2, CCNB2, FZR1, CCNA2, CDC7, YWHAQ, MCM7, CCNE1, CDK4, E2F5, CCNB1, MAD2L1, CDC25B, MCM6, BUB1, RBL1, MCM2, CDK1
  hsa03013   RNA transport                             20      1.09*E* − 07   RAN, EIF3H, NUP43, UBE2I, NUP133, MAGOHB, POP5, THOC5, CLNS1A, NUP205, GEMIN6, NUP93, NUP62, SUMO1, EIF2S2, NUP153, RANGAP1, NUP160, RPP25, DDX20
  hsa04115   p53 signaling pathway                     5       2.90*E* − 06   CCNE2, CCNB2, CCNE1, CCNB1, CDK1
  hsa04914   Progesterone-mediated oocyte maturation   8       1.42*E* − 05   CCNB2, FZR1, CCNA2, CCNB1, MAD2L1, CDC25B, BUB1, CDK1
  hsa03050   Proteasome                                9       1.56*E* − 05   PSMD7, SHFM1, PSMD3, PSMA5, PSMB1, PSMB3, PSMA3, PSMD4, PSMA7
  hsa03040   Spliceosome                               15      1.66*E* − 05   SNRPC, SRSF9, XAB2, MAGOHB, NAA38, BUD31, SNRPF, NHP2L1, SRSF3, PQBP1, USP39, SNRNP40, SNRPD1, SNRPD2, SF3B2
  hsa03030   DNA replication                           8       4.24*E* − 05   RNASEH2A, RNASEH1, MCM7, POLE2, MCM6, RNASEH2C, MCM2, RFC4
  hsa03008   Ribosome biogenesis in eukaryotes         11      4.37*E* − 05   UTP18, RAN, UTP15, NOP56, DKC1, POP5, FBL, NHP2L1, TCOF1, GNL3L, RPP25
  hsa03440   Homologous recombination                  7       4.37*E* − 05   SHFM1, MRE11A, RAD54B, XRCC2, RAD54L, BLM, TOP3A
  hsa04114   Oocyte meiosis                            8       8.96*E* − 05   CCNE2, CCNB2, YWHAQ, CCNE1, CCNB1, MAD2L1, BUB1, CDK1
  hsa05162   Measles                                   4       0.0001531      CDK6, CCNE2, CCNE1, CDK4
  hsa05222   Small cell lung cancer                    4       0.0001531      CDK6, CCNE2, CCNE1, CDK4
  hsa05200   Pathways in cancer                        23      0.0001815      VEGFB, CDK6, MTOR, FH, CCNE2, LEF1, BIRC5, CCNE1, CDK4, TCEB1, MSH6, EGF, FZD2, TFG, CKS1B, TRAF4, HSP90AA1, TRAF3, PPARG, HSP90AB1, FGF12, PIAS4, STK4
  hsa00510   N-Glycan biosynthesis                     8       0.000312       RFT1, ALG10, RPN2, ALG10B, ALG1, MOGS, ALG5, B4GALT2

EC: esophageal carcinoma; FDR: false discovery rate.

###### 

The KEGG pathway enrichment of downregulated DEGs in EC.

  KEGG ID    KEGG terms                                    Count   FDR            Genes
  ---------- --------------------------------------------- ------- -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa04144   Endocytosis                                   23      5.22*E* − 06   STAMBP, RAB11FIP5, SH3KBP1, KIT, FOLR2, F2R, TGFBR2, VPS4B, SH3GLB1, CHMP5, CXCR2, PDGFRA, CLTB, FOLR1, STAM2, ARAP2, DAB2, EEA1, PDCD6IP, RAB11FIP2, CBL, EPN3, VPS37B
  hsa04510   Focal adhesion                                19      0.000354       ITGA1, ZYX, LAMB2, MYLK, IGF1, CCND2, ITGA2, RAP1A, PDGFRA, ITGA5, TNXB, VWF, PIK3R1, JUN, COL6A2, BCL2, ROCK1, MYL12A, THBS3
  hsa04270   Vascular smooth muscle contraction            14      0.000383       JMJD7-PLA2G4B, MYLK, ADCY9, GNA13, PRKG1, ITPR2, PPP1R12B, GNAQ, MYH11, ACTG2, ROCK1, PLA2G2A, MRVI1, ITPR1
  hsa00330   Arginine and proline metabolism               4       0.000425       ALDH7A1, MAOB, GATM, MAOA
  hsa04360   Axon guidance                                 15      0.000456       EPHA1, ROBO1, SEMA4B, DPYSL2, ABLIM3, PPP3CC, NCK2, GNAI2, SEMA3F, PPP3CA, RGS3, NTN1, ROCK1, PPP3CB, EFNB2
  hsa04020   Calcium signaling pathway                     5       0.00046        PPP3CC, ITPR2, PPP3CA, PPP3CB, ITPR1
  hsa04662   B cell receptor signaling pathway             4       0.000508       PPP3CC, JUN, PPP3CA, PPP3CB
  hsa05014   Amyotrophic lateral sclerosis                 3       0.000583       PPP3CC, PPP3CA, PPP3CB
  hsa00340   Histidine metabolism                          3       0.000583       ALDH7A1, MAOB, MAOA
  hsa04720   Long-term potentiation                        6       0.000623       PPP3CC, ITPR2, GNAQ, PPP3CA, PPP3CB, ITPR1
  hsa04114   Oocyte meiosis                                6       0.00068        ADCY9, PPP3CC, ITPR2, PPP3CA, PPP3CB, ITPR1
  hsa04730   Long-term depression                          10      0.000701       JMJD7-PLA2G4B, IGF1, GNA13, PRKG1, ITPR2, PPP2CB, GNAQ, GNAI2, PLA2G2A, ITPR1
  hsa04141   Protein processing in endoplasmic reticulum   16      0.000709       SEC63, UBE2J1, EIF2AK3, ATF6, CRYAB, UBE2D3, DNAJB2, SEC31B, MAN1A1, ERO1L, BCL2, HERPUD1, DNAJC3, UBQLN2, RAD23B, LMAN1
  hsa04912   GnRH signaling pathway                        12      0.000736       JMJD7-PLA2G4B, MMP2, ADCY9, MAP3K3, HBEGF, ITPR2, MAPK7, GNAQ, MAP3K4, JUN, PLA2G2A, ITPR1
  hsa00280   Valine, leucine, and isoleucine degradation   8       0.000738       ALDH7A1, ACADM, HMGCS1, MUT, ABAT, ACADSB, ACAD8, AUH

EC: esophageal cancer; FDR: false discovery rate.

[^1]: Academic Editor: Robert Odze
